Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-450-2000
Website: http://www.jnjpharmarnd.com/
44 articles about Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
-
The U.S. FDA is expected to give the go-ahead for Pfizer and BioNTech’s COVID-19 vaccine for adolescents ages 12 and older within the week.
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Scientists Uncover Previously Unknown Role for Class of Molecules
8/4/2011
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA): In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding
4/5/2011
-
Isogenica Limited Announces Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
3/22/2011
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
8/31/2010
-
New Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Diabetes Drug, Canagliflozin Effective in Mid-Stage Study
6/28/2010
-
WuXi PharmaTech Co., Ltd. Enters into Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA), a division of Janssen Pharmaceutica for Preclinical Services and Training
3/2/2010
-
FDA Approves Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
8/3/2009
-
PPD, Inc. Confirms Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) Completion of Additional Phase III Studies Providing Expanded Safety and Efficacy Data for Priligy
6/10/2009
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain
5/7/2009
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
2/6/2009
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Progra
12/8/2008
-
FDA Approves Johnson & Johnson's (JOBS) Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
11/24/2008
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Phase II Dose-Ranging Study Demonstrates Encouraging Response Rates in Treatment of Acute Coronary Syndrome Patients
11/10/2008
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: New Data Show In Vitro Potency Of Doripenem Against Resistant Bacteria
10/27/2008
-
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Submits New Drug Application to FDA for Carisbamate
10/24/2008
-
Tekmira Pharmaceuticals Corporation Announces Presentation of Data Using SNALP RNAi Delivery Technology
10/22/2008
-
Janssen Pharmaceutica N.V. and Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: 2009 Nominations Open for The Dr. Paul Janssen Award for Biomedical Research
10/9/2008
-
U.S. FDA Seeks More Data for Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) (JOBS) Schizophrenia Drug
8/27/2008
-
FDA Requires Additional Information on Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)'s (JOBS) DORIBAX for Treatment of Hospital-Acquired Pneumonia
8/21/2008